BR0015567A - Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos - Google Patents

Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos

Info

Publication number
BR0015567A
BR0015567A BR0015567-5A BR0015567A BR0015567A BR 0015567 A BR0015567 A BR 0015567A BR 0015567 A BR0015567 A BR 0015567A BR 0015567 A BR0015567 A BR 0015567A
Authority
BR
Brazil
Prior art keywords
compositions
active agents
acid compounds
releasing active
phenoxycarboxylic acid
Prior art date
Application number
BR0015567-5A
Other languages
English (en)
Other versions
BRPI0015567B1 (pt
BRPI0015567B8 (pt
Inventor
Andrea Leone-Bay
Pinwah Tang
Jun Liao
Kelly Kraft
Destardi Moye-Sherman
John E Smart
David Gschneidner
John J Freeman Jr
Maria A P Boyd
Puchun Liu
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of BR0015567A publication Critical patent/BR0015567A/pt
Publication of BRPI0015567B1 publication Critical patent/BRPI0015567B1/pt
Publication of BRPI0015567B8 publication Critical patent/BRPI0015567B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/92—Unsaturated compounds containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSTOS DE áCIDO FENOXICARBOXìLICO E COMPOSIçõES PARA LIBERAR AGENTES ATIVOS". Provêm-se compostos de ácido fenoxicarboxílico e composições para a liberação de agentes ativos. Provêm-se também métodos de administração e preparação.
BRPI0015567A 1999-11-05 2000-11-06 composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica BRPI0015567B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16380699P 1999-11-05 1999-11-05
US23183600P 2000-09-06 2000-09-06
US23723300P 2000-10-02 2000-10-02
PCT/US2000/030662 WO2001032596A1 (en) 1999-11-05 2000-11-06 Phenoxy carboxylic acid compounds and compositions for delivering active agents

Publications (3)

Publication Number Publication Date
BR0015567A true BR0015567A (pt) 2002-07-16
BRPI0015567B1 BRPI0015567B1 (pt) 2016-10-25
BRPI0015567B8 BRPI0015567B8 (pt) 2021-05-25

Family

ID=27388931

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0015567A BRPI0015567B8 (pt) 1999-11-05 2000-11-06 composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica

Country Status (17)

Country Link
EP (2) EP1226109A4 (pt)
JP (2) JP2004501057A (pt)
KR (1) KR100788970B1 (pt)
CN (1) CN1384814B (pt)
AT (1) ATE427925T1 (pt)
AU (3) AU2622301A (pt)
BR (1) BRPI0015567B8 (pt)
CA (2) CA2390025A1 (pt)
CZ (2) CZ20021570A3 (pt)
DE (1) DE60041976D1 (pt)
HK (1) HK1048801B (pt)
HU (1) HU229415B1 (pt)
IL (4) IL149336A0 (pt)
MX (2) MXPA02004451A (pt)
NZ (1) NZ530450A (pt)
PL (1) PL201505B1 (pt)
WO (2) WO2001032130A2 (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916489B2 (en) 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
WO1997036480A1 (en) 1996-03-29 1997-10-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2339765C (en) 1998-08-07 2009-04-28 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4879433B2 (ja) 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
US7351741B2 (en) 2000-06-29 2008-04-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR0114799A (pt) 2000-09-06 2003-12-30 Emisphere Tech Inc Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
KR20030083725A (ko) * 2001-03-01 2003-10-30 에미스페어 테크놀로지스, 인코포레이티드 비스포스포네이트 전달용 조성물
US7411084B2 (en) 2001-09-26 2008-08-12 Emisphere Technologies, Inc. Method of preparing phenoxy alkanoic, alkenoic, and alkynoic acids and salts thereof via a dicarboxylate intermediate
WO2003045306A2 (en) * 2001-11-13 2003-06-05 Emisphere Technologies, Inc. Phenoxy amine compounds and compositions for delivering active agents
AU2002352974A1 (en) 2001-11-29 2003-06-10 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
EP1469827B1 (en) 2002-01-09 2017-12-27 Emisphere Technologies, Inc. Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
AU2004241242A1 (en) * 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
JP4754487B2 (ja) 2003-08-20 2011-08-24 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド（ｇｌｐ）−１化合物またはメラノコルチン４受容体（ｍｃ４）アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
CA2532026C (en) 2003-08-20 2012-04-17 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
EP1745007A2 (en) 2004-04-16 2007-01-24 Emisphere Technologies, Inc. 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
AU2005240206B2 (en) 2004-05-06 2011-04-07 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
WO2005117854A2 (en) 2004-05-14 2005-12-15 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
NZ551196A (en) 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
RU2530889C2 (ru) * 2004-05-14 2014-10-20 Эмисфире Текнолоджис, Инк. Соединения и составы для доставки активных веществ
NZ551597A (en) * 2004-05-19 2010-11-26 Emisphere Tech Inc Topical cromolyn formulations
CN1968699B (zh) 2004-05-19 2010-12-15 爱密斯菲尔科技公司 阿昔洛韦制剂
JP5749879B2 (ja) 2004-07-12 2015-07-15 エミスフェアー・テクノロジーズ・インク ペプチドｙｙおよびペプチドｙｙアゴニストの送達用組成物
AU2005271526B2 (en) 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
JP2008509933A (ja) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
AU2005321803B2 (en) 2004-12-29 2012-02-09 Emisphere Technologies, Inc. Pharmaceutical formulations of gallium salts
US8110547B2 (en) 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
FR2880887B1 (fr) * 2005-01-14 2009-01-30 Merck Sante Soc Par Actions Si Derives d'hydroxyphenols, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
US8975227B2 (en) 2005-07-15 2015-03-10 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2007121471A2 (en) 2006-04-18 2007-10-25 Emisphere Technologies, Inc. Dialkyl ether delivery agents
US8771712B2 (en) 2006-05-09 2014-07-08 Emisphere Technologies, Inc. Topical administration of acyclovir
US9364502B2 (en) 2006-06-28 2016-06-14 Emisphere Technologies, Inc. Gallium nitrate formulations
CA2661018C (en) 2006-08-18 2015-11-24 Emisphere Technologies, Inc. Synthesis of propyl phenoxy ethers and use as delivery agents
CA2662853C (en) * 2006-08-31 2016-07-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ES2657484T3 (es) 2007-02-08 2018-03-05 Emisphere Technologies, Inc. Agentes de administración de ácido fenilalquilcarboxílico
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US20110039930A1 (en) 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
WO2011097148A2 (en) * 2010-02-04 2011-08-11 Parsons Lowell C Use of oral heparin preparations to treat urinary tract diseases and conditions
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
CA3142817A1 (en) * 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013100793A1 (ru) * 2011-12-28 2013-07-04 Martynov Artur Viktorovich Производное инсулина, обладающее сахароснижающей активностью, и способ его получения
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
MX368045B (es) 2012-08-23 2019-09-17 Emisphere Tech Inc Compuestos de diisopropanolamina y dietanolamina de fenoxialquilo para la administracion de agentes activos.
CN112500338A (zh) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EP2968299B1 (en) 2013-03-15 2021-01-20 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP3919056B1 (en) 2013-03-15 2024-08-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SG10201911662YA (en) 2014-02-07 2020-02-27 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
JP6925969B2 (ja) 2015-02-09 2021-08-25 エンテラ バイオ エルティーディー． 医薬組成物
HUE072191T2 (hu) 2015-12-04 2025-10-28 Global Blood Therapeutics Inc A 2-hidoxi-6-((2-(1-izopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehid adagolási rendje
AU2017217466A1 (en) 2016-02-11 2018-08-23 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
IL321113A (en) 2016-08-17 2025-07-01 Entera Bio Ltd Formulations for oral administration of active agents
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2375138A (en) * 1942-05-01 1945-05-01 American Cyanamid Co Alkamine esters of aryloxymethyl benzoic acid
NL133069C (pt) * 1966-07-29
JPS55145648A (en) * 1979-05-02 1980-11-13 Hisamitsu Pharmaceut Co Inc New derivative of anthranylic acid
HU190774B (en) * 1979-06-29 1986-11-28 The Wellcome Foundation Ltd,Gb Process for preparing ether derivatives with pharmacological activity
JPS5750946A (en) * 1980-09-10 1982-03-25 Hisamitsu Pharmaceut Co Inc Novel anthranilic acid derivative
DE3206030A1 (de) * 1981-02-19 1982-09-09 Fuji Photo Film Co., Ltd., Minami-Ashigara, Kanagawa Verfahren zur bildung von polymeren bildern und druckplatten
IE54269B1 (en) * 1981-12-30 1989-08-02 Ici America Inc Pharmaceutically active phenylcarboxylic acid derivatives
JPS58142901A (ja) * 1982-02-19 1983-08-25 Nippon Zeon Co Ltd ゴムの変性方法
JPH0245481A (ja) * 1988-08-03 1990-02-15 Yamamura Kagaku Kenkyusho:Kk クマラン化合物の製造法
DE4142514A1 (de) * 1991-12-21 1993-06-24 Basf Ag Verfahren zur bekaempfung von pilzen
FR2687316B3 (fr) * 1992-02-13 1994-08-12 Rolland Sa A Nouvelle utilisation de compositions pharmaceutiques a base de derives phenoxyacetiques en vue de la restauration des fonctions nerveuses.
IL104283A (en) * 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate
US5364767A (en) * 1993-02-11 1994-11-15 Research Organics, In. Chromogenic compounds and methods of using same
FR2710782A1 (fr) * 1993-09-29 1995-04-07 Sodern Tube neutronique à confinement magnétique des électrons par aimants permanents et son procédé de fabrication.
US5837702A (en) * 1993-10-07 1998-11-17 Bristol-Myers Squibb Co. 4-arylamino-benzopyran and related compounds
TW270114B (pt) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5783593A (en) * 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5747537A (en) * 1995-09-05 1998-05-05 Washington University Method of inhibiting parasitic activity
JPH09207543A (ja) * 1996-02-08 1997-08-12 Denso Corp 空調装置
EP1611885A1 (en) * 1996-07-26 2006-01-04 Susan P. Perrine Use of an inducing agent for the treatment of blood, viral and cellular disorders
DE69730982T2 (de) * 1996-10-28 2005-09-01 General Mills, Inc., Minneapolis Einbettung und einkapselung von teilchen zur kontrollierten abgabe
EP1049459B1 (en) * 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
DE60041976D1 (de) 2009-05-20
JP5117658B2 (ja) 2013-01-16
HK1048801A1 (en) 2003-04-17
AU2622301A (en) 2001-05-14
AU783157B2 (en) 2005-09-29
IL195055A0 (en) 2009-08-03
HU229415B1 (en) 2013-12-30
IL149337A (en) 2010-04-15
WO2001032596A8 (en) 2001-08-09
WO2001032130A3 (en) 2002-03-14
HUP0600033A2 (en) 2006-08-28
EP1226104A4 (en) 2005-05-04
AU2005248960A1 (en) 2006-02-02
IL195055A (en) 2015-07-30
HK1048801B (en) 2009-08-28
AU2005248960B2 (en) 2009-01-29
PL201505B1 (pl) 2009-04-30
CN1384814B (zh) 2015-11-25
KR20020060222A (ko) 2002-07-16
CA2388240C (en) 2010-04-20
CA2388240A1 (en) 2001-05-10
CZ20021554A3 (cs) 2002-10-16
PL354996A1 (en) 2004-03-22
KR100788970B1 (ko) 2007-12-27
MXPA02004092A (es) 2003-02-12
EP1226109A4 (en) 2005-01-26
EP1226104A1 (en) 2002-07-31
CZ20021570A3 (cs) 2002-10-16
CA2390025A1 (en) 2001-05-10
AU1655401A (en) 2001-05-14
IL149337A0 (en) 2002-11-10
JP2004501057A (ja) 2004-01-15
EP1226104B1 (en) 2009-04-08
WO2001032596A1 (en) 2001-05-10
MXPA02004451A (es) 2002-10-23
BRPI0015567B1 (pt) 2016-10-25
JP2003513060A (ja) 2003-04-08
NZ530450A (en) 2004-06-25
EP1226109A2 (en) 2002-07-31
IL149336A0 (en) 2002-11-10
WO2001032130A2 (en) 2001-05-10
BRPI0015567B8 (pt) 2021-05-25
ATE427925T1 (de) 2009-04-15
CN1384814A (zh) 2002-12-11

Similar Documents

Publication Publication Date Title
BR0015567A (pt) Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
BR0012429A (pt) Fórmulações para il-11
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
AU7315301A (en) Compounds and compositions for delivering active agents
TR200200561T2 (tr) Mesalazin içeren ve vücut içinde kontrollü bir şekilde salgılanabilen ağızdan alınan farmasötik bileşimler
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
UY27320A1 (es) Nuevas composiciones farmacéuticas
MY129437A (en) Drug formulation having controlled release of active compound
WO2002015959A3 (en) Compounds and compositions for delivering active agents
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
FI19991806L (fi) Uusia koostumuksia biologisesti aktiivisen aineen säädettyyn vapauttamiseen, ja niiden valmistus
ITMI930582A1 (it) Composizione farmeceutiche ad attivita' analgesica
GT200100218A (es) Compuesto agroquimico.
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
CA2394471A1 (en) External preparation for treating pruritus
GEP20043231B (en) Resorcinol Composition
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
TR199900013T2 (xx) Yeni bile�ikler.

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: ATRAVES DA PETICAO NO 020924, ( 06/11/2003), O REQUERENTE SOLICITOU O EXAME DO PRESENTE E EFETUOU A RETRIBUICAO EQUIVALENTE A 21 REIVINDICACOES. NO ENTANTO, EM PETICAO NO 018080049932 ( 07/08/2008 ) FOI APRESENTADO UM NOVO QUADRO REIVINDICATORIO CONSTANDO 22 REIVINDICACOES. DESSE MODO, A FIM DE DAR CONTINUIDADE AO EXAME DO PEDIDO O REQUERENTE DEVERA COMPLEMENTAR A RETRIBUICAO EQUIVALENTE A 1 REIVINDICACAO EXCEDENTE.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REFERENTE A RPI 2028 DE 17/11/2009.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/10/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/11/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 06/11/2020